

Resource Summary Report

Generated by ASWG on Aug 10, 2026

Brilliant Violet 421(TM) anti-mouse CD4

RRID:AB_2562557

Type: Antibody

Proper Citation

BioLegend Cat# 100443, RRID:AB_2562557

Antibody Information

URL: http://antibodyregistry.org/AB_2562557

Proper Citation: BioLegend Cat# 100443, RRID:AB_2562557

Target Antigen: CD4

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC, ICC, IHC-F, SB

Antibody Name: Brilliant Violet 421(TM) anti-mouse CD4

Description: This monoclonal targets CD4

Target Organism: mouse

Clone ID: Clone GK1.5

Antibody ID: AB_2562557

Vendor: BioLegend

Catalog Number: 100443

Alternative Catalog Numbers: 100438, 100437

Record Creation Time: 20250819T230037+0000

Record Last Update: 20250820T040019+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 421(TM) anti-mouse CD4.

No alerts have been found for Brilliant Violet 421(TM) anti-mouse CD4.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 18 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Niu Y, et al. (2026) Adoptive transfer of TregIL-33 cells ameliorates acute graft-versus-host disease by regulating the HPGD/PGE2 pathway. International immunopharmacology, 168(Pt 1), 115700.

Kim DO, et al. (2026) Strain- and species-specific immune responses to human adipose stem cell-derived extracellular vesicles: A comparative pharmacological evaluation in mice and human PBMCs. European journal of pharmaceuticals and biopharmaceuticals : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 222, 115008.

Hu J, et al. (2025) CD169+ macrophages identify and eliminate tumor cells in colorectal cancer through CD169/CD43 interaction and FasL-driven apoptosis. Cell reports, 44(10), 116351.

Arnouk SM, et al. (2025) Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti-PD-1 Immunotherapy. Cancer research, 85(23), 4681.

Wang S, et al. (2025) ENPP1 inhibitor with ultralong drug-target residence time as an innate immune checkpoint blockade cancer therapy. Cell reports. Medicine, 6(9), 102336.

Wakamatsu E, et al. (2024) Indirect suppression of CD4 T cell activation through LAG-3-mediated trans-endocytosis of MHC class II. Cell reports, 43(9), 114655.

Lin M, et al. (2024) Inflammatory dendritic cells restrain CD11b+CD4+ CTLs via CD200R in human NSCLC. Cell reports, 43(2), 113767.

Oami T, et al. (2024) Claudin-2 upregulation enhances intestinal permeability, immune activation, dysbiosis, and mortality in sepsis. Proceedings of the National Academy of Sciences of the United States of America, 121(10), e2217877121.

Fanti AK, et al. (2023) Flt3- and Tie2-Cre tracing identifies regeneration in sepsis from multipotent progenitors but not hematopoietic stem cells. Cell stem cell, 30(2), 207.

Tibbs TN, et al. (2023) Mice with FVB-derived sequence on chromosome 17 succumb to disseminated virus infection due to aberrant NK cell and T cell responses. iScience,

26(11), 108348.

Meibers HE, et al. (2023) Effector memory T cells induce innate inflammation by triggering DNA damage and a non-canonical STING pathway in dendritic cells. *Cell reports*, 42(10), 113180.

Yeh CH, et al. (2022) Primary germinal center-resident T follicular helper cells are a physiologically distinct subset of CXCR5^{hi}PD-1^{hi} T follicular helper cells. *Immunity*, 55(2), 272.

Georgiadou A, et al. (2022) Comparative transcriptomic analysis reveals translationally relevant processes in mouse models of malaria. *eLife*, 11.

Chen W, et al. (2022) Chronic type I interferon signaling promotes lipid-peroxidation-driven terminal CD8⁺ T cell exhaustion and curtails anti-PD-1 efficacy. *Cell reports*, 41(7), 111647.

Yang C, et al. (2022) Androgen receptor-mediated CD8⁺ T cell stemness programs drive sex differences in antitumor immunity. *Immunity*, 55(7), 1268.

Chi X, et al. (2021) ROR γ is critical for mTORC1 activity in T cell-mediated colitis. *Cell reports*, 36(11), 109682.

Pei W, et al. (2020) Resolving Fates and Single-Cell Transcriptomes of Hematopoietic Stem Cell Clones by PolyloxExpress Barcoding. *Cell stem cell*, 27(3), 383.

Baptista AP, et al. (2019) The Chemoattractant Receptor Ebi2 Drives Intranodal Naive CD4⁺ T Cell Peripheralization to Promote Effective Adaptive Immunity. *Immunity*, 50(5), 1188.